Denver, Colorado-based DaVita Inc. (DVA) provides dialysis services to patients with chronic kidney failure in the United States. The company has a market cap of $11.3 billion and operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. DVA is expected to release its Q3 2026 earnings on Thursday, October 29, 2026, after the market closes.
Ahead of the event, analysts expect the company’s EPS to be $3.78 on a diluted basis, up 50.6% from $2.51 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in three of its last four quarters, while missing on one occasion.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts project the company’s EPS to be $14.57, up 35.2% from $10.78 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 18.4% year over year (YoY) to $17.25 in fiscal 2027.
www.barchart.com DVA stock has surged 37.1% over the past 52 weeks, outperforming the S&P 500 Index’s ($SPX) 15.2% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 23.5% rise during the same time frame.
www.barchart.com Despite outperforming the broader market over the past year, the company’s last earnings announcement did not go very well with investors. DVA stock tanked nearly 17.2% on Aug. 4, following the release of its Q2 2026 earnings. The company surpassed its adjusted EPS estimates, coming in at $4.02, and also came in line with its revenue estimate, amounting to $3.6 billion. Investors focused on weaker revenue per treatment, which fell to $415.8, mainly caused by lower dialysis enrollment due to the loss of pandemic-era ACA subsidies and reduced phosphate-binder revenue. Additionally, the company’s fiscal 2026 EPS guidance of $14.10 - $15.20 also came below analyst estimates.
Analysts are somewhat optimistic about DVA, with the stock having a “Moderate Buy” rating overall. Among the eight analysts covering the stock, three are recommending a “Strong Buy,” four suggest a “Hold,” and one suggests a “Moderate Sell.” DVA’s average analyst price target is $223.43, indicating an upside of 26.4% from the current level.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Why Deutsche Bank Wants You to Buy the Dip in CoreWeave Stock Dear Western Digital Stock Fans, Mark Your Calendars for October 22 With Robust Growth, Palantir Stock Is Worth Considering at a Premium EBAY Stock Layoffs: What to Know as eBay Plans Job Cuts for Second Time This Year